Twentyman O P, Finnerty J P, Harris A, Palmer J, Holgate S T
Medicine I, Southampton General Hospital, UK.
Lancet. 1990 Dec 1;336(8727):1338-42. doi: 10.1016/0140-6736(90)92894-n.
The effects of the long-acting beta 2-agonist salmeterol on early and late phase airways events provoked by inhaled allergen were assessed in a group of atopic asthmatic patients. In a placebo-controlled study, salmeterol 50 micrograms inhaled before allergen challenge ablated both the early and late phase of allergen-induced bronchoconstriction over a 34 h time period. Salmeterol also completely inhibited the allergen-induced rise in non-specific bronchial responsiveness over the same time period. These effects were shown to be unrelated to prolonged bronchodilatation or functional antagonism. These data suggest novel actions for topically active long-acting beta 2-agonists in asthma that extend beyond their protective action on airways smooth muscle.
在一组特应性哮喘患者中评估了长效β2激动剂沙美特罗对吸入变应原诱发的早期和晚期气道反应的影响。在一项安慰剂对照研究中，在变应原激发前吸入50微克沙美特罗可在34小时内消除变应原诱导的支气管收缩的早期和晚期阶段。沙美特罗在同一时间段内还完全抑制了变应原诱导的非特异性支气管反应性升高。这些作用被证明与延长的支气管扩张或功能拮抗无关。这些数据表明局部活性长效β2激动剂在哮喘中具有新的作用，其作用超出了对气道平滑肌的保护作用。
